Our Team

Shahnaz joined Biologics Consulting in February 2026 and has over five years of industry expertise in cell and gene therapy (CGT), with a focus on autologous CAR-T cell manufacturing and process development. She has direct experience in global technology transfer, CMC alignment, and technical support for U.S. clinical programs.

She is skilled in IND-enabling workstreams, having managed portfolios for multiple clinical programs and facilitated the transfer of acquired assets from international markets, including Germany and China. Her expertise extends to authoring and reviewing critical regulatory and process documentation, including IND applications, master batch records, and technical reports. She is also highly proficient in deviation management, risk assessments, and troubleshooting for clinical-scale manufacturing.

Prior to joining Biologics Consulting, Shahnaz served as a Process Engineer at BioNTech, where she drove global technology transfers and spearheaded the transition to automated formulation systems. Previously, at AstraZeneca, she managed a portfolio of five clinical programs and established critical supply chain infrastructure. Shahnaz has a deep technical command of end-to-end automation platforms, including the Miltenyi CliniMACS Prodigy, Cytiva Sepax/Sefia, and Gibco CTS DynaCellect Magnetic Separation System. Her foundational career also includes translational research at The Jackson Laboratory, focusing on iPSC-based disease modeling.

Shahnaz has authored five peer-reviewed publications in high-impact journals such as Cell Reports and Circulation and holds a pending patent for a CRISPR-based therapeutic treatment for dilated cardiomyopathy. She received her B.S. in Biomedical Engineering from Worcester Polytechnic Institute (WPI) in 2019.